BBHC
NTLA icon

Brown Brothers Harriman & Co’s Intellia Therapeutics NTLA Stock Holding History

Brown Brothers Harriman & Co’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-35
Closed -$3K – 1377
2022
Q1 		$3K Buy
+35
New +$2.96K ﹤0.01% 1169

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Brown Brothers Harriman & Co's NTLA Position: Q2 2022 in Review

Brown Brothers Harriman & Co sold out of Intellia Therapeutics (NTLA) in Q2 2022, closing a stake of 35 shares — an estimated $3K sold.

Brown Brothers Harriman & Co first reported a position in NTLA in Q1 2022 and held it in 1 quarter. The position peaked at $3K in Q1 2022. 299 funds tracked by Wall St. Rank hold NTLA as of Q2 2022.

  • Brown Brothers Harriman & Co reported no remaining Intellia Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 35 Intellia Therapeutics shares in Q2 2022, an estimated $3K.
  • Brown Brothers Harriman & Co first reported a position in Intellia Therapeutics in Q1 2022 and held it in 1 quarter.
  • Brown Brothers Harriman & Co's Intellia Therapeutics position peaked at $3K in Q1 2022.
  • 299 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2022.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2022, filed 11 Aug 2022.